Oxidative stress involvement in α-synuclein oligomerization in Parkinson's disease cybrids

Antioxidants and Redox Signaling

Volumn 11, Issue 3, 2009, Pages 439-448

  Esteves, A Raquel ^a   Arduíno, Daniela M ^a   Swerdlow, Russell H ^b   Oliveira, Catarina R ^a,c   Cardoso, Sandra M ^a,c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA SYNUCLEIN; CARBONYL DERIVATIVE; GLUTATHIONE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); THIOL DERIVATIVE; TUBULIN; UBIDECARENONE; BIOPOLYMER; UBIQUINONE;

ADULT; AGED; ARTICLE; CELL LINE; COMPARATIVE STUDY; CONTROLLED STUDY; CYBRID; DEPOLYMERIZATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MICROTUBULE; MITOCHONDRION; OLIGOMERIZATION; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CARBONYLATION; ANALOGS AND DERIVATIVES; IMMUNOHISTOCHEMISTRY; METABOLISM; POLYACRYLAMIDE GEL ELECTROPHORESIS; WESTERN BLOTTING;

ALPHA-SYNUCLEIN; BIOPOLYMERS; BLOTTING, WESTERN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GLUTATHIONE; HUMANS; IMMUNOHISTOCHEMISTRY; OXIDATIVE STRESS; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES; UBIQUINONE;

EID: 58849086657     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2008.2247     Document Type: Article

References (46)

1. Alim MA, Hossain MS, Arima K, Takeda K, Izumyama Y, Nakamura M, Kaji H, Shinoda T, Hisanaga S, and Uéda K. Tubulin seeds alpha-synuclein fibril formation. J Biol Chem 277: 2112-2117, 2002.
2. Benzi G and Moretti A. Age- and peroxidative stress-related modifications of the cerebral enzymatic activities linked to mitochondria and the glutathione system. Free Radic Biol Med 19: 77-101, 1995.
3. Beyer K. Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol 112: 237-251, 2006.
4. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
5. + affects microtubule dynamics by acting as a destabilizing factor. FEBS Lett 579: 4781-4786, 2005.
6. Cardoso SM, Moreira PI, Agostinho P, Pereira C, and Oliveira CR. Neurodegenerative pathway in Parkinson's disease: therapeutical strategies. Curr Drugs Targets-CNS&ND 4: 405-419, 2005.
7. Cardoso SM, Santana I, Swerdlow RH, and Oliveira CR Mitochondrial dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J Neurochem 89: 1417-1426, 2004.
8. Cassarino DS, Fall CP, Swerdlow RH, Smith TS, Halvorsen EM, Miller SW, Parks JP, Parker WD Jr, and Bennett JP Jr. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim Biophys Acta 1362: 77-86, 1997.
9. Cookson MR and Brug M. Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp Neurol 1: 5-11, 2007.
10. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, and Marsden CD. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381, 1989.
11. Di Monte D, Ross D, Bellomo G, Eklow L, and Orrenius S. Alterations in intracellular thiol homeostasis during the metabolism of menadione by isolated rat hepatocytes. Arch Biochem Biophys 235: 334-342, 1984.
12. Dickson DW, Liu W, Hardy J, Farrer M, Mehta N, Uitti R, Mark M, Zimmerman T, Golbe L, Sage J, Sima A, D'Amato C, Albin R, Gilman S, and Yen SH. Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol 155: 1241-1251, 1999.
13. Domingues AF, Arduíno DM, Esteves ARF, Swerdlow RH, Oliveira CR, and Cardoso SM. Mitochondria and ubiquitin-proteasomal system interplay: relevance to Parkinson's disease. Free Radic Biol Med 45: 820-825, 2008.
14. Esteves ARF, Domingues AF, Arduíno D, Nunes-Correia I, Januário C, Swerdlow RH, Oliveira CR, and Cardoso SM. Mitochondrial dysfunction towards protein aggregation in Parkinson's disease: contribution of microtubule depolymerization. Soc Neurosci Abstracts S7: 370.7, 2007.
15. Esteves ARF, Domingues AF, Ferreira IL., Januário C, Swerdlow RH, Oliveira CR, and Cardoso SM. Mitochondrial dysfunction occurs in Parkinson's disease cybrids containing an nt2 neuron-like nuclear background. Mitochondrion 8: 219-228, 2008.
16. Floor E and Wetzel MG. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 70: 268, 1998.
17. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55: 259, 1996.
18. Gelb DJ, Oliver E, and Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 56: 33-39, 1999.
19. Giasson BI, Ischiropoulos H, Lee VM-Y, and Trojanowski JQ. The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. Free Radic Biol Med 32: 1264-1275, 2002.
20. Halda A and Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol 193: 279-290, 2005.
21. Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, and Masliah E. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro. Neuroreport 10: 717-721, 1999.
22. Hattori N, Tanaka M, Ozawa T, and Mizuno Y. Immunohistochemical studies on complexes I, II, III, IV of mitochondria in Parkinson's disease. Ann Neurol 30: 563-571, 1991.
23. Kang JH and Kim KS. Enhanced oligomerization of the alpha-synuclein mutant by the Cu,Zn-superoxide dismutase and hydrogen peroxide system. Mol Cells 15: 87-93, 2003.
24. Kim M, Jung W, Lee IH, Bhak G, Paik SR, and Hahn JS. Impairment of microtubule system increases alpha-synuclein aggregation and toxicity. Biochem Biophys Res Commun doi:10.1016/j.bbrc.2007.11.020, 2007.
25. Krige D, Carrol MT, Cooper JM, Marsden CD, and Schapira AHV. Platelet mitochondrial function in Parkinson's disease: the Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol 32: 782-788, 1992.
26. Levine RL, Williams JA, Stadtman ER, and Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol 233: 346-357, 1994.
27. Mårtensson J, Lai JC, and Meister A. High-affinity transport of glutathione is part of a multicomponent system essential for mitochondrial function. Proc Natl Acad Sci U S A 87: 7185-7189, 1990.
28. Moussa CE, Wersinger C, Tomita Y, and Sidhu A. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine. Biochemistry 43: 5539-5550, 2004.
29. Nunomura A, Moreira PI, Lee HG, Zhu X, Castellani RJ, Smith MA, and Perry G. Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. CNS Neurol Disord Drug Targets 6: 411-423, 2007.
30. Ono K and Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 97: 105-115, 2006.
31. Ragan CI, Wilson MT, Darley-Usmar VM, and Lowe PN. Subfractionation of mitochondria, and isolation of the proteins of oxidative phosphorylation. In Mitochondria, A Practical Approach edited by Darley-Usmar VH, Rickwood D, and Wilson HT. London: IRL Press, 1987, pp. 79-112.
32. Ren Y and Feng J. Rotenone selectively kills serotonergic neurons through a microtubule-dependent mechanism. J Neurochem 103: 303-311, 2007.
33. Sayre LM, Moreira PI, Smith MA, and Perry G. Metal ions and oxidative protein modification in neurological disease. Ann Ist Super Sanità 41: 143-164, 2005.
34. Schapira A, Cooper JM, Dexter D, Clark JB, Jenner P, and Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54: 823-827, 1990.
35. Schulz JB, Lindenau J, Seyfried J, and Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 267: 4904, 2000.
36. Shults CW, Haas RH, Passov D, and Beal MF. Coenzyme Q(10) levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and non-parkinsonian subjects. Ann Neurol 42: 261-264, 1997.
37. Souza JM, Giasson BI, Chen Q, Lee VM, and Ischiropoulos H. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers: implications of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 275: 18344-18349, 2000.
38. Stocchi V, Cucchiarini L, Chiarantini L, Palma P, and Crescentini G. Simultaneous extraction and reverse-phase high-performance liquid chromatographic determination of adenine and pyridine nucleotides in human red blood cells. Anal Biochem 146:118-124, 1985.
39. Swerdlow RH, Parks JK, Cassarino DS, Maguire DJ, Maguire RS, Bennett JP Jr, Davis RE, and Parker WD Jr. Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology 49: 918-925, 1997.
40. Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP, Bennett JP Jr, Davis RE, and Parker WD Jr. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 40: 663-671, 1996.
41. Takahashi M, Ko LW, Kulathingal J, Jiang P, Sevlever D, and Yen SH. Oxidative stress-induced phosphorylation, degradation and aggregation of alpha-synuclein are linked to upregulated CK2 and cathepsin D. Eur J Neurosci 26: 863-874, 2007.
42. Trimmer PA, Borland MK, Keeney PM, Bennett JP Jr, and Parker WD Jr. Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies. J Neurochem 88: 800-812, 2004.
43. Turnbull S, Tabner BJ, El-Agnaf OM, Moore S, Davies, Y, and Allsop D. Alpha-synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic Biol Med 30: 1163-1170, 2001.
44. Uversky VN. Neuropathology, biochemistry, and biophysics of α-synuclein aggregation. J Neurochem doi:10.1111/j.1471-4159.2007. 04764, 2007.
45. Winkler-Stuck K, Wiedemann FR, Wallesch CW, and Kunz WS. Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients. J Neurol Sci 220: 41-48, 2004.
46. Ziegler DM. Role of reversible oxidation-reduction of enzyme thiols-disulfides in metabolic regulation. Annu Rev Biochem 54: 305-329, 1985.